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Viral loads in clinical specimens and 
SARS manifestations
Key Messages
1. A high viral load in 
nasopharyngeal aspirate (with 
or without a high viral load in 
serum) is a useful prognostic 
indicator of respiratory failure 
or mortality. The presence of 
viral RNA in multiple body 
sites is also indicative of poor 
prognosis. 
2. Early treatment with an effective 
antiviral agent before day 10 
may decrease the peak viral 
load, and thus ameliorate the 
clinical symptoms and mortality, 
and reduce viral shedding and 
the risk of transmission.
Hong Kong Med J 2009;15(Suppl 9):S20-2
Introduction
The SARS pandemic affected 8098 people with 774 fatalities in 2002-2003.1 
A novel coronavirus was isolated from SARS patients who had specific 
seroconversion to this virus.2-4 Animal models using macaque monkeys, ferrets 
and domestic cats were established. However, no extrapulmonary lesions could 
be identified in these animals though virus isolation and real-time polymerase 
chain reaction (RT-PCR) for viral RNA were positive from their pharyngeal 
secretions, tracheobronchial secretions, urine, rectal swabs or stool, kidney or 
lung tissues. We reported the use of RT-PCR to detect SARS-CoV RNA from 
nasopharyngeal aspirate (NPA), throat swab, urine and stool specimens. We also 
developed RT-qPCR assays using the LightCycler System (Idaho Technology, 
Idaho Falls [ID], US) to augment the sensitivity of detection. The serial viral load 
in NPA was used for monitoring the clinical progress and the response to anti-
viral therapy, whereas the admission viral load in serum was used as a marker 
of prognosis. Unlike the animal models, extrapulmonary manifestations such 
as haematological changes, diarrhoea, and liver derangement were common in 
SARS patients. In this study, we assayed and analysed the viral load of clinical 
specimens from different anatomic sites between days 10 to 15 after the onset of 
symptoms to understand the role of this virus in the pathogenesis of the clinical 
manifestations and abnormal laboratory tests in SARS patients.
Aims and objectives
To correlate SARS-CoV viral load in different clinical specimens with the clinical 
manifestations of SARS.
Methods 
Patients who fulfilled the modified World Health Organization definition of 
SARS (n=154), managed in the United Christian Hospital and Caritas Medical 
Centre were included in this quantitative virological study. All patients were 
either serologically confirmed by demonstrating a four-fold rise of indirect 
immunofluoresent antibody titre against SARS-CoV in the serum taken on 
admission and within day 28 after symptoms onset, or had positive RT-PCR for 
SARS-CoV RNA confirmed from their clinical specimens (for those who died 
or failed to seroconvert before day 28). The case definition included fever of 
38ºC or higher, cough or shortness of breath, and new pulmonary infiltrates on 
chest radiography or high-resolution computed tomography in the absence of 
an alternative diagnosis to explain the clinical presentation. During the first 15 
days, patients were prospectively monitored for occurrence of diarrhoea, oxygen 
desaturation, mechanical ventilation, and laboratory evidence of lymphopaenia, 
renal impairment, liver dysfunction, abnormal urinalysis, and mortality. For the 
diagnosis of SARS-CoV infection, NPA and acute sera were taken on admission. 
Convalescent sera were taken between days 7 and 28 after the onset of symptoms. 
In all patients, RT-PCR for SARS-CoV was performed on the NPA collected on 
admission. RT-qPCR was performed for patients who had their NPA, sera, stool 
and urine specimens collected on days 10 to 15 after the onset of symptoms. All 
virological diagnostic laboratory tests including viral culture, RT-PCR, RT-qPCR 
and immunofluorescent antibody detection for IgG seroconversion against SARS-
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CoV were performed according to our protocols. From 
clinical samples, RNA was extracted using the QIAamp virus 
RNA mini kit (Qiagen) as instructed by the manufacturer. 
For all specimens, 140 µL of the sample were used for 
RNA extraction and extracted RNA was finally eluted in 
30 µL of RNase-free water and stored at -20ºC. For the RT-
qPCR assay, RNA and cDNA was generated as described; 
cDNA was amplified in a 7000 Sequence Detection System 
(Applied Biosystems) by using TaqMan PCR Core Reagent 
kit (Applied Biosystems). In a typical reaction, 2 µL of 
cDNA was amplified in a 25 µL reaction containing 0.625 U 
AmpliTaq Gold polymerase (Applied Biosystems), 2.5 µL of 
10x TaqMan buffer A, 0.2 mM of dNTPs, 5.5 mM of MgCl2, 
2.5 U of AmpErase UNG, and 1x primers-probe mixture 
(Assays by Design, Applied Biosystems). The forward 
primer was 5'-CAGAACGCTGTAGCTTCAAAAATCT-
3' (corresponding to nt 17718 to 17742 of SARS-
CoV genome) and the reverse primer was 5'-
T C A G A A C C C T G T G AT G A AT C A A C A G - 3 ' 
(complementary to nt 17761 to 17785). The sequence of 
the reporter probe was 5'-(FAM)TCTGCGTAGGCAA
TCC(NFQ)-3' (FAM, 6-carboxyfluorescein; NFQ, non-
fluorescent quencher; complementary to nt 17745 to 17760). 
Reactions were first incubated at 50ºC for 2 min, followed 
by 95ºC for 10 min. Reactions were then thermal-cycled 
for 40 cycles (95ºC for 15 sec, 60ºC for 1 min). Plasmids 
containing the target sequences were used as standard 
controls. To monitor the integrity of RNA extraction for 
each sample, a housekeeping gene, beta-actin was detected 
by RT-PCR using two primers: beta-actin forward, 5'-
CCCAAGGCCAACCGCGAGAAGAT-3' and reverse, 5'-
GTCCCGGCCAGCCAGGTCCAG-3'. All samples were 
found to contain detectable beta-actin RNA.
Statistical analysis
All timed data were calculated from the onset of symptoms. 
We compared the viral load in these specimens with the 
presence or absence of diarrhoea, oxygen desaturation, 
mechanical ventilation, lymphopaenia, hepatic dysfunction, 
abnormal urinalysis and mortality by Chi squared or Fisher’s 
exact test for categorical variables and Mann-Whitney U 
test for continuous variables. A two-tailed P value of less 
than 0.05 was taken to be significant. Correlation between 
the number of anatomical sites with detectable viral 
load by RT-qPCR and mortality was calculated by linear 
regression.
Results
Viral load in NPA (n=142) between days 10 and 15 after the 
onset of symptoms was associated with oxygen desaturation 
(odds ratio [OR]=3.1; 95% confidence interval [CI], 1.6-
6.2), mechanical ventilation (OR=11.3; 95% CI, 3.6-35.1), 
diarrhoea (OR=2.5; 95% CI, 1.3-5), hepatic dysfunction 
(OR=2.5; 95% CI, 1.2-5.2) and mortality (OR=54; 95% 
CI, 7-415). Serum viral load (n=53) was associated with 
oxygen desaturation (OR=5; 95% CI, 1.5-16.4), mechanical 
ventilation (OR=1.5; 95% CI, 1.1-2) and mortality 
(OR=17.1; 95% CI, 2.0-151). Stool viral load (n=94) was 
associated with diarrhoea (OR=14.1; 95% CI, 1.7-114), 
as was urine viral load (n=111) with abnormal urinalysis 
(OR=7.2; 95% CI, 1.6-32.9).
Discussion 
The viral load reflects the dynamic interaction between viral 
replication and viral clearance by body defence mechanisms. 
Viral load study in SARS has been used for virological 
diagnosis and monitoring of progress or response to anti-
viral therapy. In our study, the viral load in the NPA peaked 
around day 10 and was immediately followed by a decrease 
with a concomitant normalisation of the lymphocyte count 
and a corresponding rise of serum antibodies specific for 
the SARS-CoV. The presence of the virus and the viral load 
in different body fluids may have a bearing on the possible 
modes of transmission. The infectivity at day 10 as reflected 
by a mean peak viral load of 5.8 and 7.0 log10 copies/mL 
in positive specimens of NPA and stool respectively 
suggested that respiratory droplets and indirect contact with 
faeces might be an important mechanism of transmission. 
Previous viral load study centred on NPA and serum at the 
time of admission as a diagnostic tool and a prognostic 
indicator. Viral load study in various body fluids in addition 
to NPA and serum has not been performed to determine the 
transmission and pathogenesis of the pulmonary and extra-
pulmonary manifestations of SARS. 
 The SARS is predominantly a viral pneumonia with 
a rapid tempo of deterioration. The importance of SARS-
CoV as a respiratory pathogen is supported by the strong 
association of the viral load in the NPA with oxygen 
desaturation, mechanical ventilation and mortality as 
evident by odds ratios of 3.1, 11.3 and 54 respectively. 
Unexpectedly it was also associated with diarrhoea 
(OR=2.5) and hepatic dysfunction (OR=2.5). Anecdotal 
reports of the usefulness of steroids in the treatment of 
SARS suggest these extra-pulmonary manifestations could 
just be part of an inflammatory spill-over from a process of 
virus induced immuno-dysregulation or excessive cytokine 
activation in the lungs. However, our findings suggest that 
viral replication in these extra-pulmonary sites may be as 
important since the viral load in the stool correlated strongly 
with diarrhoea. Moreover, electron microscopy of the ileal 
and colonic biopsy from SARS patients showed numerous 
viral particles intra- and extra-cellularly.
 The serum viral load also correlated with oxygen 
desaturation, mechanical ventilation, and mortality. This 
was not surprising, as viraemia has also been reported 
in adenovirus, respiratory syncytial virus and rotavirus 
infections.5-7 However, viraemia even if present is very short 
lasting in these mucosal infections. In one study, five out of 
41 neonates with positive respiratory syncytial virus (RSV) 
antigen in nasal washes were positive for RSV-RNA in blood. 
High levels of adenovirus DNA in serum was also associated 
with fatal outcome in children who developed adenovirus 
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infection after allogeneic stem-cell transplantation. Six 
(86%) of seven children who died of adenovirus infection, 
compared with only two (7%) of 29 other patients, had high 
serum levels of adenoviral DNA (P<0.0001). The absence 
of an association between viral load in any specimens with 
lymphopaenia at day 10 could be explained by the routine 
use of steroids which induces apoptosis of lymphocytes. 
The apparent inferior performance of serum viral load as 
a prognostic indicator could be related to a lower number 
of available serum samples in this cohort. However, the 
proportion who had oxygen desaturation in these 53 (38%) 
patients was not significantly different from the 142 (46%) 
patients who had submitted nasopharyngeal samples between 
days 10 and 15.
 Compared with other common viral respiratory diseases, 
the onset of peak viral load in the nasopharynx appeared 
to be delayed. In a prospective study of viral shedding in 
nasopharyngeal secretions in experimental adult infections 
as enumerated by TCID 50 (median tissue culture infective 
dose) viral titre or RT-qPCR, RSV was detected between 
days 2 and 12, with a plateau phase between days 3 and 
8 at a peak viral load of 5 log10 copies/mL. In the case of 
experimental adult influenza, viral replication in NPA 
peaked at about 48 hours after the onset of symptoms and 
declined sharply thereafter, with an insignificant degree of 
viral shedding after days 6 to 8. The peak virus titres in 
symptomatic volunteers inoculated with influenza A H3N2 
ranged from 102.5 to 107.0 TCID50/mL of nasopharyngeal 
wash. The viral load correlated positively with the clinical 
symptoms of fever and malaise, as well as the degree of viral 
shedding. However, the reported low incidence of viraemia 
and the early peak nasopharyngeal viral load in these two 
conditions could be accounted by the inherent behaviour 
of viral replication, background IgG and IgA antibodies 
with cross-reactivity against homologous antigens (due 
to previous infections or innate immunity of the host). In 
many of these experimental infections where the profile 
of the viral load in NPA was documented, the volunteers 
were adults and had a low level of background antibodies 
and therefore concomitant cell mediated immunity against 
influenza or RSV. 
 One limitation of the present study was its retrospective 
nature. Only those who had sent the specimen at around day 
10 could be tested and analysed. Changes of lymphocyte 
subset were also not analysed due to the retrospective 
nature of this study. Nonetheless, lymphocytes changes in 
SARS patients were well reported by two other groups who 
showed a consistent decrease in the peripheral blood level of 
dendritic cell subsets, natural killer cells, CD4+ and CD8+ 
T lymphocytes and B lymphocytes in SARS patients.8,9 
Conclusions
SARS is predominantly a respiratory infection with spread 
through viraemia to extrapulmonary sites where viral 
replication leads to non-respiratory manifestations. There 
could be concomitant immuno-dysregulation and associated 
inflammatory damage that accentuates its morbidity and 
mortality. A high viral load in NPA with or without a high 
viral load in serum is a useful prognostic indicator of 
respiratory failure or mortality. The presence of viral RNA 
in multiple body sites is also indicative of a poor prognosis. 
Early treatment with an effective antiviral agent before day 
10 may decrease the peak viral load, and thus ameliorate 
clinical symptoms and mortality, and reduce viral shedding 
and the risk of transmission.
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